To date, ONL has raised nearly $10 million through a combination of traditional financing efforts and securing of research grants.
Most recently, the company completed a $4.25 million Series A financing round that involved both existing and new investors including Novartis, the University of Michigan’s Michigan Investment in New Technology Startups (MINTS) program, Capital Community Angels, Invest Michigan, Biosciences Research & Commercialization Center and Hestia Investments.
The proceeds from the Series A financing, combined with a recent $1 million grant from the National Eye Institute, will enable ONL to finalize preclinical development of ONL1204 in preparation for clinical trials in retinal detachment. The funds will also be used to support the broadening of the company’s research of ONL1204 into other retinal diseases with significant unmet needs.
To find out more about investing in ONL Therapeutics, please contact us at:
1600 Huron Pkwy
Building 520, Second Floor
Ann Arbor, MI 48109